Bass, Berry & Sims healthcare fraud attorney, John Kelly, comments on the recent DOJ and SEC investigations of nearly every major pharmaceutical and medical device manufacturer regarding potential violations of the Foreign Corrupt Practices Act (FCPA) after an Indian parliamentary panel alleged abuses in the country's drug approval process. The DOJ has also shown interest in examination of potential corruption in the clinical trials process.
"With clinical trials, you're going to have constant interaction with either foreign officials or entities that are operated by government entities," John Kelly said. "If they weren't (looking at it), they will be now."
The full article published by Thomson Reuters and titled "India drugs inquiry could prompt new U.S. scrutiny," can be found here.